Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.
2.

Imputing missing standard deviations in meta-analyses can provide accurate results.

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N.

J Clin Epidemiol. 2006 Jan;59(1):7-10.

PMID:
16360555
3.

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.

Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS.

Ann Intern Med. 2005 Sep 20;143(6):415-26. Review.

PMID:
16172440
4.

The power of statistical tests for moderators in meta-analysis.

Hedges LV, Pigott TD.

Psychol Methods. 2004 Dec;9(4):426-45.

PMID:
15598097
5.

Meta-analysis of raw mean differences.

Bond CF Jr, Wiitala WL, Richard FD.

Psychol Methods. 2003 Dec;8(4):406-18.

PMID:
14664679
6.

Measuring inconsistency in meta-analyses.

Higgins JP, Thompson SG, Deeks JJ, Altman DG.

BMJ. 2003 Sep 6;327(7414):557-60. Review. No abstract available.

7.
8.

Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database.

Khan A, Leventhal RM, Khan SR, Brown WA.

J Clin Psychopharmacol. 2002 Feb;22(1):40-5.

PMID:
11799341
9.

Publication bias in meta-analysis: its causes and consequences.

Thornton A, Lee P.

J Clin Epidemiol. 2000 Feb;53(2):207-16. Review.

PMID:
10729693
10.

Somatotopic activation of opioid systems by target-directed expectations of analgesia.

Benedetti F, Arduino C, Amanzio M.

J Neurosci. 1999 May 1;19(9):3639-48.

11.

A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.

Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT.

J Clin Psychiatry. 1998 Mar;59(3):116-22.

PMID:
9541154
12.

Investigating underlying risk as a source of heterogeneity in meta-analysis.

Thompson SG, Smith TC, Sharp SJ.

Stat Med. 1997 Dec 15;16(23):2741-58.

PMID:
9421873
13.

Clinical evaluation of venlafaxine.

Ballenger JC.

J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):29S-35S; discussion 35S-36S. Review.

PMID:
8784646
14.

Dose-response relationship with venlafaxine.

Kelsey JE.

J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):21S-26S; discussion 26S-28S. Review.

PMID:
8784645
15.

Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study.

Mendels J, Johnston R, Mattes J, Riesenberg R.

Psychopharmacol Bull. 1993;29(2):169-74.

PMID:
8290661
16.

A comparison of venlafaxine, trazodone, and placebo in major depression.

Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E.

J Clin Psychopharmacol. 1994 Apr;14(2):99-106. Erratum in: J Clin Psychopharmacol 1994 Aug;14(4):292.

PMID:
8195464
17.

A double-blind comparison of nefazodone, imipramine, and placebo in major depression.

Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, Ecker JA, Faludi G.

J Clin Psychiatry. 1994 Jun;55(6):234-41.

PMID:
8071277
18.

Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.

Schweizer E, Feighner J, Mandos LA, Rickels K.

J Clin Psychiatry. 1994 Mar;55(3):104-8.

PMID:
8071246
19.

Nefazodone and imipramine in major depression: a placebo-controlled trial.

Rickels K, Schweizer E, Clary C, Fox I, Weise C.

Br J Psychiatry. 1994 Jun;164(6):802-5.

PMID:
7952987
20.

A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.

Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF.

J Clin Psychiatry. 1995;56 Suppl 6:30-6.

PMID:
7649971

Supplemental Content

Support Center